Original article| Volume 60, ISSUE 7, P777-783, October 01, 2006

Download started.


Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder


      Although disulfiram and naltrexone have been approved by the Food and Drug Administration for the treatment of alcoholism, the effect of these medications on alcohol use outcomes and on psychiatric symptoms is still unknown in patients with co-occurring disorders post-traumatic stress disorder (PTSD).


      Patients (n = 254) with a major Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in a medication study at three Veterans Administration outpatient clinics. Randomization included (1) open randomization to disulfiram or no disulfiram; and (2) double-blind randomization to naltrexone or placebo. This resulted in four groups: (1) naltrexone alone; (2) placebo alone; (3) disulfiram and naltrexone; or (4) disulfiram and placebo. Outcomes were measures of alcohol use, PTSD symptoms, alcohol craving, GGT levels and adverse events.


      93 individuals (36.6%) met DSM-IV criteria for PTSD. Subjects with PTSD had better alcohol outcomes with active medication (naltrexone, disulfiram or the combination) than they did on placebo; overall psychiatric symptoms of PTSD improved. Individuals with PTSD were more likely to report some side effects when treated with the combination.


      The results of this study suggest that disulfiram and naltrexone are effective and safe for individuals with PTSD and comorbid alcohol dependence.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Anton R.F.
        • Moak D.H.
        • Latham P.
        The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior.
        Alcoholism: Clin Exp Res. 1995; 19: 92-99
        • Anton R.F.
        • Moak D.H.
        • Latham P.K.
        The Obsessive Compulsive Drinking Scale: A new method of assessing outcome in alcoholism treatment studies.
        Arch Gen Psychiatry. 1996; 53 ([published erratum appears in Arch Gen Psychiatry 1996 Jul;53(7):576]): 225-231
        • Bills L.J.
        • Kreisler K.
        Treatment of flashbacks with naltrexone.
        Am J Psychiatry. 1993; : 150
        • Blake D.D.
        • Weathers F.W.
        • Nagy L.M.
        • Kaloupek D.G.
        • Klauminzer G.
        • Charney D.S.
        • Keane T.M.
        A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1.
        Behav. Ther. 1990; 13: 187-188
        • Bremner J.D.
        • Southwick S.M.
        • Darnell A.
        • Charney D.S.
        Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse.
        Am J Psychiatry. 1996; 153: 369-375
        • Carroll K.M.
        • Nich C.
        • Ball S.A.
        • McCance E.
        • Rounsaville B.J.
        Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram.
        Addiction. 1998; 93: 713-727
        • Croop R.S.
        • Faulkner E.B.
        • Labriola D.F.
        The safety profile of naltrexone in the treatment of alcoholism.
        Arch Gen Psychiatry. 1997; 54: 1130-1135
        • Derogatis L.R.
        • Lipman R.S.
        • Rickels K.
        • Uhlenhuth E.H.
        • Covi L.
        The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory.
        Behav Sci. 1974; 19: 1-15
        • Erb S.
        • Shaham Y.
        • Stewart J.
        Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period.
        Psychopharmacol. 1996; 128: 408-412
        • Farren C.K.
        • O’Malley S.S.
        Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
        Am J Psychiatry. 1999; 156: 1258-1262
        • First M.D.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV Axis I Disorders (Patient Edition) (SCID-P). Biometric Research, New York State Psychiatric Institute, New York, N.Y1996
        • Fisher C.M.
        ‘Catatonia’ due to disulfiram toxicity.
        Arch Neurol. 1989; : 46
        • Glover H.
        A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder.
        Israel Journal of Psychiatry & Related Sciences. 1993; 30: 255-263
        • Hedeker D.
        • Gibbons R.
        • Davis J.
        Random regression models for multicenter clinical trials data.
        Psychopharmacology Bulletin. 1991; 27: 73-77
        • Herbeck D.M.
        • Fitek D.J.
        • Svikis D.S.
        • Montoya I.D.
        • Marcus S.C.
        • West J.C.
        Treatment Compliance in Patients with Comorbid Psychiatric and Substance Use Disorders.
        The American Journal on Addictions. 2005; 14: 195-207
        • Ibarra P.
        • Bruehl S.P.
        • McCubbin J.A.
        • Carlson C.R.
        • Wilson J.F.
        • Norton J.A.
        • Montgomery T.B.
        An unusual reaction to opioid blockade with naltrexone in a case of post-traumatic stress disorder.
        Journal of Traumatic Stress. 1994; 7 ([see comment]): 303-309
        • Jacobsen L.K.
        • Southwick S.M.
        • Kosten T.R.
        Substance use disorders in patients with posttraumatic stress disorder: a review of the literature.
        American Journal of Psychiatry. 2001; 158: 1184-1190
        • Karamanakos P.N.
        • Pappas P.
        • Stephanou P.
        • Marselos M.
        Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism.
        Pharmacology & Toxicology. 2001; 88: 106-110
        • Kessler R.C.
        • Sonnega A.
        • Bromet E.
        • Hughes M.
        • Nelson C.B.
        Posttraumatic stress disorder in the National Comorbidity Survey.
        Archives of General Psychiatry. 1995; 52: 1048-1060
        • Koob G.F.
        Corticotropin-releasing factor, norepinephrine, and stress.
        Biol Psychiatry. 1999; 46: 1167-1180
        • Larson E.W.
        • Olincy A.
        • Rummans T.A.
        • Morse R.M.
        Disulfiram Treatment of Patients with both Alcohol Dependence and Other Psychiatric Disorders.
        Alcohol Clin Exp Res. 1992; 16: 125-130
        • Lubin G.
        • Weizman A.
        • Shmushkevitz M.
        • Valevski A.
        Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.
        Human Psychopharmacology. 2002; 17: 181-185
        • Maxwell S.
        • Shinderman M.S.
        Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness.
        Journal of Addictive Diseases. 2000; 19: 61-69
        • Morris P.L.
        • Hopwood M.
        • Whelan G.
        • Gardiner J.
        • Drummond E.
        Naltrexone for alcohol dependence: a randomized controlled trial.
        Addiction. 2001; 96 ([comment]): 1565-1573
        • Mueser K.
        • Noordsy D.
        • Fox L.
        • Wolfe R.
        Disulfiram Treatment for Alcoholism in Severe Mental Illness.
        The American Journal on Addictions. 2003; 12: 242-252
        • Petrakis I.L.
        • Poling J.
        • Levinson C.
        • Nich C.
        • Rounsaville B.
        Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders.
        Biological Psychiatry. 2005; 57: 1128-1137
        • Piazza P.V.
        • Deminiere J.M.
        • le Moal M.
        • Simon H.
        Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration.
        Brain Research. 1990; 514: 22-26
        • Rieger D.A.
        • Farmer M.E.
        • Rae D.S.
        Comorbidity of mental disorders with alcohol and other drug abuse.
        JAMA. 1990; 264: 2511-2518
        • Salloum I.
        • Cornelius J.
        • Thase M.
        • Daley D.
        • Kirisci L.
        • Spotts C.
        Naltrexone Utility in Depressed Alcoholics.
        Psychopharmacology. 1998; 34: 111-115
        • Shaham Y.
        • Stewart J.
        Stress reinstates heroin-seeking in drug-free animals: an effect mimicking heroin, not withdrawal.
        Psychopharmacology. 1995; 119: 334-341
        • Sinha R.
        • Catapano D.
        • O’Malley S.
        Stress-induced craving and stress response in cocaine dependent individuals.
        Psychopharmacology. 1999; 142: 343-351
        • Skinner H.A.
        • Horn J.L.
        Alcohol Dependence Scale (ADS): User’s Guide. Addiction Research Foundation, Toronto1984
        • Sobell L.C.
        • Sobell M.B.
        Timeline Follow-Back: A technique for assessing self-reported alcohol consumption.
        in: Litten R. Allen J. Measuring Alcohol Consumption. The Humana Press, Totowa NJ1992